Cell and gene therapies from academia: EMA to help 5 projects going after unmet clinical needs

29 Sep 2022
endpts.com
Gene TherapyCell Therapy
The European Medicines Agency said Thursday that it’s launching a new pilot program to help academic and other nonprofit researchers developing advanced therapy medicinal products, which includes cell and gene therapies. Academics have proven to be enormously useful in feeding new products, like chimeric antigen receptor (CAR)-T cell therapies first developed by Memorial Sloan Kettering, and ushered to the market by biopharma companies. Jean Bennett , formerly with the University of Pennsylvania, also saw her research lead to the approval of gene therapy Luxturna, which Roche now owns. EMA says that for this pilot it will guide five participants through the regulatory process with the aim to optimize the development of the ATMPs, starting from best practice principles for manufacturing to planning clinical development. “The pilot’s first participant has already been selected,” EMA said, noting that it’s ARI-0001, a CAR-T product based on patients’ own T-cells, developed by the Hospital Clínic Barcelona. The product has already received authorization from the Spanish Agency of Medicines and Medical Devices under a “hospital exemption” approval pathway for the treatment of patients aged >25 years with relapsed/refractory acute lymphoblastic leukemia. In December 2021, ARI-0001 was granted eligibility to PRIME , EMA’s scheme to support the development of medicines that target an unmet medical need. “The pilot participants will benefit from all the available regulatory flexibilities and development support measures, such as fee reductions and waivers,” EMA added in a statement . “The progress will be closely monitored, and initial results of the pilot are expected to be available in 3-4 years.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.